Comparison of the Effect of Compound CDRI 80/53 [N-(3-acetyl-4,5-dihydro-2-furanyl)-N4-(6 -methoxy-8-quinolinyl)1,4- pentanediamine] with Primaquine on Human Erythrocytes In Vitro

Abstract

Comparative in vitro study of a malaria antirelapse compound CDRI Code 80/53 with primaquine (PQ) was done on the erythrocytes of eight normal and six G-6-PD-deficient individuals. Reduced glutathione (GSH) was estimated in the RBCs exposed to the in vitro action of the drugs. Statistically significant decreases were observed at 25 ug/ml and 50 µ/ml doses of PQ as compared t the equivalent doses of compound 80/53 in both normal and G-6-PD-deficient erythrocytes. The study showed that compound CDRI 80/53 did not damage normal as well as G-6-PD-deficient erythrocytes to the same extent as PQ.